[HTML][HTML] Drugging PI3K in cancer: refining targets and therapeutic strategies

TA Yap, L Bjerke, PA Clarke, P Workman - Current opinion in pharmacology, 2015 - Elsevier
Highlights•PI3K is an important target for innovative anticancer drug development and
precision medicine.•Over 30 small molecule PI3K inhibitors are currently in clinical trial
testing.•These drugs include dual PI3K/mTOR, pan-Class I PI3K and isoform-selective PI3K
inhibitors.•The PI3Kδ inhibitor idelalisib has received FDA approval for the treatment of B-
cell malignancies.•Drug resistance, patient selection and development of targeted
combinations remain challenges.The phosphatidylinositol-3 kinase (PI3K) pathway is one of …